You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

QUADRAMET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Quadramet, and what generic alternatives are available?

Quadramet is a drug marketed by Lantheus Medical and is included in one NDA.

The generic ingredient in QUADRAMET is samarium sm-153 lexidronam pentasodium. Additional details are available on the samarium sm-153 lexidronam pentasodium profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for QUADRAMET?
  • What are the global sales for QUADRAMET?
  • What is Average Wholesale Price for QUADRAMET?
Summary for QUADRAMET
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 8
Clinical Trials: 3
Drug Prices: Drug price information for QUADRAMET
What excipients (inactive ingredients) are in QUADRAMET?QUADRAMET excipients list
DailyMed Link:QUADRAMET at DailyMed
Drug patent expirations by year for QUADRAMET
Drug Prices for QUADRAMET

See drug prices for QUADRAMET

Recent Clinical Trials for QUADRAMET

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1/Phase 2
Mayo ClinicPhase 1/Phase 2
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityPhase 1

See all QUADRAMET clinical trials

US Patents and Regulatory Information for QUADRAMET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medical QUADRAMET samarium sm-153 lexidronam pentasodium INJECTABLE;INJECTION 020570-001 Mar 28, 1997 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for QUADRAMET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0164843 C980021 Netherlands ⤷  Sign Up PRODUCT NAME: SAMARIUM[153 SM] LEXIDRONAM, DESGEWENST IN DE VORM VAN EEN FYSI OLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET PENTANATRIUMZO UT; NAT.REGISTRATION NO/DATE: C(1998)253 DEF 19980205; FIRST REGISRATION: EU/1/97/057/001 19980205
0164843 SPC/GB98/028 United Kingdom ⤷  Sign Up PRODUCT NAME: 153 SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONIC ACID (QUADRAMET); REGISTERED: CH CH 54265 19971006; UK EU/1/97/057/001 19980205
0164843 98C0023 Belgium ⤷  Sign Up PRODUCT NAME: SAMARIUM (153 SM) LEXIDRONAM PENTASODIQUE; NAT. REGISTRATION NO/DATE: EU/1/97/057/001 19980205; FIRST REGISTRATION: CH 54265 19971006
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.